These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27088953)

  • 1. Lack of efficacy of liposomal glucantime in the treatment of cutaneous leishmaniasis.
    Ghoyonlo VM; Jafari MR; Yazdanpanah MJ; Esmaili H; Noori S; Kiafar B
    Indian J Dermatol Venereol Leprol; 2016; 82(3):347-9. PubMed ID: 27088953
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
    Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
    Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
    Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
    Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
    [No Abstract]   [Full Text] [Related]  

  • 4. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M; Behnaz F; Golshan Z
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Back from the Peace Corps--with skin lesions from South America.
    Sorci JJ; Cordova X; Usatine RP
    J Fam Pract; 2003 Jul; 52(7):531-6. PubMed ID: 12884834
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Moradi S; Derakhshan R; Haftbaradaran E
    BMC Complement Altern Med; 2007 Apr; 7():13. PubMed ID: 17466071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G; Nilforoushzadeh MA
    Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: a single-blind randomized clinical trial.
    Daie Parizi MH; Karvar M; Sharifi I; Bahrampour A; Heshmat Khah A; Rahnama Z; Baziar Z; Amiri R
    Dermatol Ther; 2015; 28(3):140-6. PubMed ID: 25847678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symmetrical cutaneous leishmaniasis.
    Guarneri C; Guarneri F
    Acta Derm Venereol; 2005; 85(3):281-2. PubMed ID: 16040429
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 45 year old man with an ulcerated nodule on his right leg.
    Fernández-Crehuet P; Ruiz-Villaverde R
    BMJ; 2014 Sep; 349():g5296. PubMed ID: 25202145
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
    Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
    Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.